Table 1.
Characteristics of patients according to pathologic nodal status.
| All Patients Her2-Positive | pN0 | pN0(i+) | pN1mi | pN1 Macro | Chi 2 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nb | % | Nb | % | Nb | % | Nb | % | p | ||
| Total | 1047 | 59.1 | 60 | 3.4 | 118 | 6.7 | 546 | 30.8 | ||
| Age | median | 56 | 54 | 54.3 | 54 | |||||
| mean | 56.2 | 53.4 | 55.2 | 55 | ||||||
| Age groups | ≤40 | 113 | 10.8 | 12 | 20.0 | 17 | 14.4 | 77 | 14.1 | 0.007 |
| 40.1–50 | 234 | 22.3 | 12 | 20.0 | 35 | 29.7 | 135 | 24.7 | ||
| 50.1–74.9 | 628 | 60.0 | 32 | 53.3 | 53 | 44.9 | 281 | 51.5 | ||
| ≥75 | 72 | 6.9 | 4 | 6.7 | 13 | 11.0 | 53 | 9.7 | ||
| Tumor size | median | 13 | 15 | 16 | 23.5 | |||||
| mean | 15.1 | 17.1 | 18.9 | 29.9 | ||||||
| pT size groups | <20 mm | 781 | 74.6 | 35 | 58.3 | 72 | 61.0 | 194 | 35.5 | <0.0001 |
| ≥20 mm | 240 | 22.9 | 25 | 41.7 | 43 | 36.4 | 344 | 63.0 | ||
| Unknown | 26 | 2.5 | 0 | 0 | 3 | 2.5 | 8 | 1.5 | ||
| SLNB | No | 113 | 10.8 | 0 | 0 | 4 | 3.4 | 183 | 33.5 | <0.0001 |
| Yes | 934 | 89.2 | 60 | 100 | 114 | 96.6 | 363 | 66.5 | ||
| ALND | No | 829 | 79.2 | 24 | 40.0 | 27 | 22.9 | 47 | 8.6 | <0.0001 |
| Yes | 218 | 20.8 | 36 | 60.0 | 91 | 77.1 | 499 | 91.4 | ||
| Grade SBR | 1 | 103 | 9.8 | 5 | 8.3 | 11 | 9.3 | 23 | 4.2 | <0.0001 |
| 2 | 490 | 46.8 | 33 | 55.0 | 50 | 42.4 | 220 | 40.3 | ||
| 3 | 425 | 40.6 | 21 | 35.0 | 56 | 47.5 | 298 | 54.6 | ||
| Unknown | 29 | 2.8 | 1 | 1.7 | 1 | 0.8 | 5 | 0.9 | ||
| LVI | No | 745 | 71.2 | 32 | 53.3 | 61 | 51.7 | 226 | 41.4 | <0.0001 |
| Yes | 170 | 16.2 | 25 | 41.7 | 52 | 44.1 | 283 | 51.8 | ||
| Unknown | 132 | 12.6 | 3 | 5.0 | 5 | 4.2 | 37 | 6.8 | ||
| Subtype | ER-negative | 331 | 31.6 | 21 | 35.0 | 33 | 28.0 | 225 | 41.2 | 0.001 |
| ER-positive | 715 | 68.4 | 39 | 65.0 | 85 | 72.0 | 321 | 58.8 | ||
| Chemotherapy | No | 345 | 33.0 | 11 | 18.3 | 8 | 6.8 | 34 | 6.2 | <0.0001 |
| Yes | 702 | 67.0 | 49 | 81.7 | 110 | 93.2 | 512 | 93.8 | ||
| Trastuzumab | No | 487 | 46.5 | 20 | 33.3 | 27 | 22.9 | 178 | 32.6 | <0.0001 |
| Yes | 560 | 53.5 | 40 | 66.7 | 91 | 77.1 | 368 | 67.4 | ||
| Endocrine | ||||||||||
| Therapy | No | 385 | 36.8 | 29 | 48.3 | 39 | 33.1 | 246 | 45.1 | 0.002 |
| Yes | 662 | 63.2 | 31 | 51.7 | 79 | 66.9 | 300 | 54.9 | ||
| Surgery | BCS | 758 | 72.4 | 35 | 58.3 | 79 | 66.9 | 260 | 47.6 | <0.0001 |
| Mastectomy | 268 | 25.6 | 25 | 41.7 | 39 | 33.1 | 275 | 50.4 | ||
| Unknown | 21 | 2.0 | 0 | 0 | 0 | 0 | 11 | 2.0 | ||
| Radiotherapy | No | 195 | 18.6 | 11 | 18.3 | 12 | 10.2 | 23 | 4.2 | <0.0001 |
| Yes (1449) | 780 | 74.5 | 49 | 81.7 | 106 | 89.8 | 514 | 94.1 | ||
| Unknown | 72 | 6.9 | 0 | 0 | 0 | 0 | 9 | 1.6 | ||
| RNI * | No | 477 | 72.5 | 19 | 50.0 | 26 | 28.9 | 39 | 8.5 | <0.0001 |
| Yes | 181 | 27.5 | 19 | 50.0 | 64 | 71.1 | 422 | 91.5 | ||
| Follow-up | median | 58.79 | 62.70 | 67.00 | 63.95 | |||||
| Recurrence | No | 970 | 92.6 | 54 | 90.0 | 104 | 88.1 | 444 | 81.3 | <0.0001 |
| Yes | 77 | 7.4 | 6 | 10.0 | 14 | 11.9 | 102 | 18.7 | ||
| Metastases | No | 1001 | 95.9 | 57 | 95.0 | 106 | 90.6 | 458 | 84.5 | <0.0001 |
| Yes | 43 | 4.1 | 3 | 5.0 | 11 | 9.4 | 84 | 15.5 | ||
| Death | No | 994 | 94.9 | 58 | 96.7 | 115 | 97.5 | 470 | 86.1 | <0.0001 |
| Yes | 53 | 5.1 | 2 | 3.3 | 3 | 2.5 | 76 | 13.9 | ||
Legend: RNI: regional nodal irradiation, * RNI 1247 known for 1449 with radiotherapy, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, LVI: lympho vascular invasion, ER: endocrine receptors, BCS: breast conservative surgery.